CALCULATE YOUR SIP RETURNS

Sun Pharma Sells 100% Stake in Japanese Arm

Updated on: Jan 17, 2025, 1:26 PM IST
Sun Pharmaceutical Industries Ltd. shares gain as company to sell 100% stake in Japanese subsidiary Sun Pharma Japan Technical Operations.
Sun Pharma Sells 100% Stake in Japanese Arm
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Sun Pharmaceutical Industries Limited (commonly known as Sun Pharma) is one of India’s leading multinational pharmaceutical companies and the largest pharmaceutical company in India by market capitalisation and revenue. Founded in 1983 by Dilip Shanghvi, Sun Pharma specialises in producing generic medications, branded formulations, and speciality products.

Agreement with Zaza Industrial 

The company has entered into an agreement with Zaza Industrial Holdings K.K., Japan, under which Sun Pharma has agreed to sell 100% of the shares held in Sun Pharma Japan Technical Operations, a step-down subsidiary of the company (through its subsidiary, Sun Pharma Japan Limited). 

Consequently, Sun Pharma Japan Technical Operations will cease to be a subsidiary of the company. The expected date for the completion of the sale/disposal is January 31, 2025.

Sun Pharma Q2 FY25 Results

Sun Pharmaceutical Industries Limited reported strong financial results for Q2 FY25, with gross sales of ₹13,264 crore, a 10.5% year-on-year (YoY) increase, and net profit rising 28% YoY to ₹3,040 crore. EBITDA grew by 23.9% YoY to ₹3,939 crore, with a margin of 29.6%. 

The India Formulations segment contributed ₹4,265 crore in sales (up 11% YoY), while the U.S. Formulations segment saw a 20.3% YoY growth to $517 million. Global speciality sales grew 19.2% YoY to $286 million. The results reflect strong demand for speciality drugs and robust performance in both the Indian and U.S. markets.

Share Price Performance 

Sun Pharmaceutical Industries Ltd. share price traded at ₹1,894.00 per share at the end of the market today.

Join millions of happy investors and traders. Download the Angel One mutual fund app now and stay connected to the market wherever you are!

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Jan 2, 2025, 1:40 PM IST

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2.5 Cr+ happy customers